Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase NA 1Phase 2 1

Status

Completed 58Terminated 19Unknown 17Recruiting 16Active not recruiting 12Not yet recruiting 6Withdrawn 3

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Colorectal Neoplasms 12Pancreatic Neoplasms 6Cholangiocarcinoma 4Cirrhosis, Familial, with Pulmonary Hypertension 3Esophageal Neoplasms 2Biliary Tract Neoplasms 2Stomach Neoplasms 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1PDAC - Pancreatic Ductal Adenocarcinoma 1Neoplasms, Second Primary 1Neoplasm, Residual 1Neoplasm Metastasis 1Locally Advanced Low Rectal Adenocarcinoma 1Liver Neoplasms 1Liver Metastases of Colorectal Cancer 1Gastroesophageal Junction Cancer 1Esophageal Squamous Cell Carcinoma 1Efficacy and Safety 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1CRC 1Biliary Cancer Metastatic 1Appendiceal Neoplasms 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Gemcitabine 20130-nm albumin-bound paclitaxel 8irinotecan sucrosofate 7Oxaliplatin 6Leucovorin 6Fluorouracil 6Taxes 5Drug Therapy 5Albumin-Bound Paclitaxel 4toripalimab 3S 1 (combination) 3Paclitaxel 3Injections 3surufatinib 2camrelizumab 2Specimen Handling 2Pemetrexed 2Pancreaticoduodenectomy 2Irinotecan 2Exercise 2Capecitabine 2Blood Specimen Collection 2zimberelimab 1sintilimab 1potassium oxonate 1pembrolizumab 1nimotuzumab 1netrin-1 inhibitor NP137 1gimeracil 1folfirinox 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Not yet recruiting × Pancreatic Neoplasms × Leucovorin × Clear all
NCT07325214 2026-01-12

Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer

IMGT Co., Ltd.

Phase NA Not yet recruiting
136 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT07262567 2025-12-03

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

Genfleet Therapeutics (Shanghai) Inc.

Phase 3 Not yet recruiting
320 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06370754 2024-04-17

FD-IMPACT

Fudan University

Phase 1/2 Not yet recruiting
117 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06259058 2024-03-15

Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 1/2 Not yet recruiting
96 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06217042 2024-01-22

HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer

Fudan University

Phase 3 Not yet recruiting
524 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06210360 2024-01-18

Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

Changhai Hospital

Phase 2 Not yet recruiting
134 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡